Physician profile
Christopher L Corless
NPI 1568477065
$32,130.32
in general payments reported to CMS, 2019-2025
5 companies · $4,230 in 2025
The $4,230 reported for 2025 was more than what 84% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,938 · 2020: $8,902 · 2021: $7,830 · 2023: $4,230 · 2025: $4,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $23,811.61 | 2019-2025 | |
| Amgen INC. | $4,988.30 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $1,800.00 | 2021 | |
| Roche Molecular Systems, INC. | $1,500.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $30.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Corless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.